Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Yahoo Finance · Nov 3, 9:01 PM
Ardelyx completes enrollment in constipation drug trial - Investing.com
Investing.com · Nov 3, 1:21 PM
Ardelyx is a commercial-stage company selling two forms of tenapanor: IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for high phosphate in dialysis patients.
Ardelyx's case rests on IBSRELA reaching $1 billion in annual revenue, with XPHOZAH as a second product. IBSRELA revenue grew 23% to $96.3 million, and reduced 2026 guidance remains unchanged, but payer access and the billion-dollar timeline remain key uncertainties. XPHOZAH grew 7% and retained its annual outlook; long-term guidance remains withdrawn. ACCEL, the Phase 3 trial in adults with chronic idiopathic constipation, completed enrollment ahead of schedule, with topline data expected in the second half of 2027.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: IBSRELA growth recovers despite payer restrictions
Can IBSRELA deliver its maintained annual outlook while payer access improves?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
IBSRELA outlook maintained; ACCEL fully enrolled, with payer access still central
Two approved tenapanor products fund a constipation label expansion, after Ardelyx lost its CMS reimbursement lawsuit over XPHOZAH
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Kidney diseases, Liver and digestive diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.